• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine.中和 VUI B.1.1.28 P2 变异株的血清来自 COVID-19 康复患者和 Covaxin（一种灭活 COVID-19 疫苗）的接种者。
J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab077.
2
Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin.用 COVID-19 恢复期患者和灭活 COVID-19 疫苗 BBV152/Covaxin 接种者的血清中和 Beta 和 Delta 变异株。
J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab104.
3
Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.灭活新冠疫苗BBV152/COVAXIN可有效中和最近出现的新冠病毒B.1.1.7变异株。
J Travel Med. 2021 Jun 1;28(4). doi: 10.1093/jtm/taab051.
4
Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.BNT162b2疫苗诱导产生的针对真实B.1、B.1.1.7、B.1.351、B.1.525和P.1型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的中和抗体血清学调查
Emerg Microbes Infect. 2021 Dec;10(1):1241-1243. doi: 10.1080/22221751.2021.1940305.
5
Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152.与接种 BBV152 的个体血清相比，对 SARS-CoV-2 Delta AY.1 和 Delta 的中和作用相当。
J Travel Med. 2021 Dec 29;28(8). doi: 10.1093/jtm/taab154.
6
Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern.新冠病毒灭活疫苗BBV152（Covaxin）的加强针可增强针对阿尔法、贝塔、德尔塔和奥密克戎等变异株的中和抗体反应。
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taac039.
7
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
8
Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naïve vaccinees.与仅接种两剂疫苗的未感染过新冠病毒的人群相比，新冠康复者和接种Covaxin疫苗后出现突破性感染病例的血清对奥密克戎的中和能力有所提高。
J Infect. 2022 Jun;84(6):834-872. doi: 10.1016/j.jinf.2022.03.016. Epub 2022 Mar 19.
9
Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.异源加强 COVID-19 疫苗接种方案的免疫原性和安全性：ChAdOx1 疫苗 Covishield 加 BBV152 疫苗 Covaxin。
J Travel Med. 2021 Dec 29;28(8). doi: 10.1093/jtm/taab166.
10
Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals.用Covishield™疫苗接种者和新冠康复后接种疫苗者的血清中和德尔塔变种。
J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab119.

引用本文的文献

1
Neutralizing antibody levels as a key factor in determining the immunogenic efficacy of the novel PEDV alpha coronavirus vaccine.中和抗体水平是决定新型猪流行性腹泻病毒α冠状病毒疫苗免疫原性效力的关键因素。
Vet Q. 2025 Dec;45(1):1-20. doi: 10.1080/01652176.2025.2509506. Epub 2025 May 28.
2
Clinical characterization, molecular and genomic sequencing analysis of SARS-Cov-2 during second wave at Raigarh, Chhattisgarh, India.印度恰蒂斯加尔邦赖加德第二波新冠疫情期间新冠病毒的临床特征、分子及基因组测序分析
Bioinformation. 2024 Sep 30;20(9):1059-1064. doi: 10.6026/9732063002001059. eCollection 2024.
3
Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India.印度成年人对 AZD1222/Covishield 和 BV152/Covaxin COVID-19 疫苗的体液和细胞免疫反应。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2410579. doi: 10.1080/21645515.2024.2410579. Epub 2024 Oct 21.
4
The status of COVID-19 vaccines in India: A review.印度新冠疫苗的现状：综述
Vacunas. 2023 Apr 25. doi: 10.1016/j.vacun.2023.04.003.
5
Variants of SARS-CoV-2: Influences on the Vaccines' Effectiveness and Possible Strategies to Overcome Their Consequences.SARS-CoV-2 变异株：对疫苗效力的影响及克服其后果的可能策略。
Medicina (Kaunas). 2023 Mar 5;59(3):507. doi: 10.3390/medicina59030507.
6
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines.2019冠状病毒病最新情况：严重急性呼吸综合征冠状病毒2变种、抗病毒药物及疫苗
Heliyon. 2023 Mar;9(3):e13952. doi: 10.1016/j.heliyon.2023.e13952. Epub 2023 Feb 23.
7
Efficacy and Safety of COVID-19 Vaccines-An Update.新型冠状病毒肺炎疫苗的疗效与安全性——最新进展
Diseases. 2022 Nov 23;10(4):112. doi: 10.3390/diseases10040112.
8
An Analysis of the COVID-19 Situation in India in Terms of Testing, Treatment, Vaccine Acceptance and National Economic Performance.从检测、治疗、疫苗接种和国民经济表现方面分析印度的 COVID-19 形势。
Int J Public Health. 2022 Nov 2;67:1604975. doi: 10.3389/ijph.2022.1604975. eCollection 2022.
9
A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects.全面综述 BBV152 疫苗的研发、效力、安全性、挑战与前景。
Front Immunol. 2022 Sep 13;13:940715. doi: 10.3389/fimmu.2022.940715. eCollection 2022.
10
Inactivated vaccine Covaxin/BBV152: A systematic review.灭活疫苗Covaxin/BBV152：一项系统评价。
Front Immunol. 2022 Aug 9;13:863162. doi: 10.3389/fimmu.2022.863162. eCollection 2022.

中和 VUI B.1.1.28 P2 变异株的血清来自 COVID-19 康复患者和 Covaxin（一种灭活 COVID-19 疫苗）的接种者。

Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine.

机构信息

Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India.

Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana, India.

出版信息

J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab077.

DOI:10.1093/jtm/taab077
PMID:34002240
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8194512/
Abstract

Our study has shown 1.09 and 1.92 fold reductions in the neutralizing titer with sera of individuals with natural infection and Covaxin vaccine recipients against B.1.1.28.2 variant.

摘要

我们的研究表明，与自然感染个体的血清和 Covaxin 疫苗接种者的血清相比，针对 B.1.1.28.2 变异株的中和滴度分别降低了 1.09 倍和 1.92 倍。